Endo International PLC (NASDAQ:ENDP) (TSE:ENL) issued an update on its third quarter earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $0.85 for the period, compared to the Thomson Reuters consensus estimate of $0.67. The company issued revenue guidance of $785 million, compared to the consensus revenue estimate of $784.88 million.Endo International PLC also updated its FY17 guidance to $3.35-3.65 EPS.
Endo International PLC (ENDP) opened at $6.09 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.02 and a debt-to-equity ratio of 10.20. The firm has a market cap of $1,359.85, a P/E ratio of 1.23 and a beta of 0.53. Endo International PLC has a 1 year low of $5.77 and a 1 year high of $18.63.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last posted its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.06. The firm had revenue of $786.90 million during the quarter, compared to analysts’ expectations of $794.93 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The company’s revenue was down 11.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.01 earnings per share. research analysts predict that Endo International PLC will post 3.54 EPS for the current year.
A number of
analysts have recently weighed in on the stock. Royal Bank Of Canada reduced their price objective on shares of Endo International PLC from $9.00 to $8.00 and set a sector perform rating for the company in a research note on Friday. Cowen and Company reissued a hold rating and issued a $16.00 price target on shares of Endo International PLC in a report on Thursday, August 10th. Oppenheimer Holdings, Inc. reissued a hold rating on shares of Endo International PLC in a report on Tuesday, August 8th. Deutsche Bank AG set a $13.00 target price on shares of Endo International PLC and gave the stock a buy rating in a report on Wednesday, August 9th. Finally, BMO Capital Markets reiterated a market perform rating and set a $11.00 price target (down previously from $15.00) on shares of Endo International PLC in a research report on Friday, August 11th. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have issued a buy rating to the company. The company has an average rating of Hold and a consensus target price of $12.58.
In other news, CFO Blaise Coleman purchased 6,500 shares of the business’s stock in a transaction dated Tuesday, August 15th. The shares were purchased at an average cost of $7.89 per share, with a total value of $51,285.00. Following the completion of the purchase, the chief financial officer now owns 13,729 shares of the company’s stock, valued at approximately $108,321.81. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have bought 16,000 shares of company stock worth $125,460 over the last three months. Insiders own 0.50% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.